Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 11/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9911121 | 0.77 | CYP19A1 (0.45) | CYP19A1MAPTP2RX7CDC7CDK2 | |
| SCHEMBL112058 | 0.75 | KMT2A (0.60) | CYP19A1MAPTP2RX7CDC7CDK2 | |
| SCHEMBL29796527 | 0.74 | CDK4 (0.61) | — | |
| SCHEMBL1779994 | 0.74 | CDK4 (0.61) | — | |
| SCHEMBL31536146 | 0.74 | P2RX7 (0.47) | CYP19A1MAPTP2RX7CDC7CDK2 | |
| SCHEMBL2547264 | 0.74 | P2RX7 (0.47) | CYP19A1MAPTP2RX7CDC7CDK2 | |
| SCHEMBL4133896 | 0.73 | CDK4 (0.37) | CYP19A1MAPTCDC7CDK2CYP2A6 | |
| SCHEMBL27368447 | 0.73 | CYP19A1 (0.45) | CYP19A1MAPTCDC7CDK2RAPGEF4 | |
| SCHEMBL24437335 | 0.72 | DYRK1A (0.52) | CYP19A1MAPTP2RX7CDC7CDK2 | |
| SCHEMBL18926929 | 0.72 | KCNH2 (0.50) | CYP19A1MAPTP2RX7CDC7CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450317-B2 | CXCR3 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| EP-2424840-A1 | CXCR3 RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| US-20100280028-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | US | disclosed |
| WO-2010126811-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280028-A1 | CXCR3 RECEPTOR ANTAGONISTS | CXCR3, CXCR1, CXCR2 | CYP19A1 2285/4885MAPT 4724/4885P2RX7 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.